Merck partners with Isomorphic Labs on AI-driven cancer drug discovery
MRK•Merck entered a research collaboration with Isomorphic Labs to use AI to discover small-molecule candidates against an oncology target. Isomorphic Labs is eligible for milestone payments and tiered royalties, and can opt to co-fund development for higher royalties.
1. Research collaboration
Merck will provide proprietary data for Isomorphic Labs to use with its AI drug design engine to generate molecular designs against a strategically important oncology target. Merck will handle preclinical and clinical development, manufacturing and commercialization of products resulting from the collaboration. Isomorphic Labs will receive an upfront payment, may receive milestone payments and tiered royalties on net sales, and can opt to co-fund development in exchange for higher royalties.




